Stockholm, 2013-11-18 14:03 CET (GLOBE NEWSWIRE) --
In consultation with the largest shareholders, the Chairman of PledPharma has established a Nomination Committee for the 2014 Annual General Meeting that is to be held on April 8. The committee consists of Staffan Persson, Peter Lindell, Gunnar Lindberg and Håkan Åström (Chairman of PledPharma). Staffan Persson will act as convener for the Nomination Committee.
The Committee's task is to present proposals regarding Chairman and other members of the board and fees and other remuneration to the Board´s members. The Nominating Committee shall also submit proposals for appointment and remuneration of auditors. Further, the Committee shall submit proposals to the process to appoint the Nomination Committee for the AGM in 2015.
Shareholders who wish to submit proposals to the Nomination Committee can do so by e-mail: hakanastrom@aol.com
For more information please contact:
Håkan Åström, Chairman
Phone: +46 703 747 213
Jacques Näsström, CEO
Phone: +46 737 130 979
jacques.nasstrom@pledpharma.se
About PledPharma
PledPharma is a Swedish specialty pharma company that develops PledOx® for prevention of severe chemotherapy-induced side effects in cancer patients. Due to these side effects optimal treatment cannot be carried out. The current market for supportive cancer care is some SEK 72 billion. PledOx protects normal cells against oxidative stress. It belongs to a group of compounds named lowMEM (low Molecular Enzyme Mimetics), and mimics the enzyme Manganese SuperOxide Distmutase (MnSOD) – the most important endogenous cellular protectant against devastating oxidative stress. Oxidative stress is a condition caused by harmful oxygen/nitrogen molecules, e.g., as a result of chemotherapy treatment. The company is also evaluating opportunities of using PLED substances in other diseases. PledPharma (STO:PLED) is listed on NASDAQ OMX First North. Erik Penser Bankaktiebolag is the Certified Adviser. For further information, please visit www.pledpharma.se
